Last Updated: May 31, 2026

Patent: 8,247,536

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,247,536

Title:	Factor VIII compositions
Abstract:	Conjugates of a Factor VIII moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided are compositions comprising the conjugates, methods of making the conjugates, and methods of administering compositions comprising the conjugates to a patient.
Inventor(s):	Bossard Mary J., Bentley Michael D., Zhang Ping
Assignee:	Nektar Therapeutics
Application Number:	US12636594
Patent Claims:	see list of patent claims
Patent landscape, scope, and claims summary:	Insufficient information to produce a complete and accurate analysis of United States Patent 8,247,536. More… ↓ ⤷ Start Trial

Details for Patent 8,247,536

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Wyeth Pharmaceuticals Llc	REFACTO	antihemophilic factor (recombinant)	For Injection	103779	June 27, 2001	⤷ Start Trial	2029-12-11
Wyeth Pharmaceuticals Llc	REFACTO	antihemophilic factor (recombinant)	For Injection	103779	July 06, 2001	⤷ Start Trial	2029-12-11
Takeda Pharmaceuticals U.s.a., Inc.	ADYNOVATE	antihemophilic factor (recombinant), pegylated	For Injection	125566	November 13, 2015	⤷ Start Trial	2029-12-11
Takeda Pharmaceuticals U.s.a., Inc.	ADYNOVATE	antihemophilic factor (recombinant), pegylated	For Injection	125566	October 25, 2016	⤷ Start Trial	2029-12-11
Takeda Pharmaceuticals U.s.a., Inc.	ADYNOVATE	antihemophilic factor (recombinant), pegylated	For Injection	125566	March 13, 2017	⤷ Start Trial	2029-12-11
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 8,247,536

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2004075923	⤷ Start Trial
United States of America	9999657	⤷ Start Trial
United States of America	8889831	⤷ Start Trial
United States of America	8618259	⤷ Start Trial
United States of America	8519102	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.